Candesartan CilexetilAn Update of its Use in Essential Hypertension

被引：0
|
作者：
Stephanie E. Easthope
Blair Jarvis
机构：
[1] Adis International Limited,
来源：
Drugs | 2002年 / 62卷
关键词：
Losartan; Hydrochlorothiazide; Valsartan; Candesartan; Irbesartan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1253 / 1287
页数：34
相关论文
共 50 条
  • [1] Candesartan cilexetil - An update of its use in essential hypertension
    Easthope, SE
    Jarvis, B
    DRUGS, 2002, 62 (08) : 1253 - 1287
  • [2] Candesartan cilexetil - A review of its use in essential hypertension
    McClellan, KJ
    Goa, KL
    DRUGS, 1998, 56 (05) : 847 - 869
  • [3] Candesartan CilexetilA Review of its Use in Essential Hypertension
    Karen J. McClellan
    Karen L. Goa
    Drugs, 1998, 56 : 847 - 869
  • [4] Comparison of candesartan versus enalapril in essential hypertension
    Zanchetti, A
    Omboni, S
    AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (02) : 129 - 134
  • [5] Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
    Chikhladze, N. M.
    Sivakova, O. A.
    Blinova, E. V.
    Sakhnova, T. A.
    Kolos, I. P.
    Litonciva, G. N.
    Chazova, I. E.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2008, 7 (07): : 34 - 38
  • [6] Candesartan cilexetil plus hydrochlorothiazide combination - A review of its use in hypertension
    Melian, EB
    Jarvis, B
    DRUGS, 2002, 62 (05) : 787 - 816
  • [7] Candesartan Cilexetil plus Hydrochlorothiazide CombinationA Review of its Use in Hypertension
    Ezequiel Balmori Melian
    Blair Jarvis
    Drugs, 2002, 62 : 787 - 816
  • [8] COMPARISON STUDY OF CANDESARTAN AND BENAZEPRIL TREATMENT OF ESSENTIAL HYPERTENSION
    Liu Peiliang
    HEART, 2012, 98 : E257 - E257
  • [9] Candesartan cilexetil - A pharmacoeconomic review of its use in chronic heart failure and hypertension
    Plosker, Greg L.
    Keam, Susan J.
    PHARMACOECONOMICS, 2006, 24 (12) : 1249 - 1272
  • [10] Candesartan CilexetilA Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension
    Greg L. Plosker
    Susan J. Keam
    PharmacoEconomics, 2006, 24 : 1249 - 1272
12345